Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma-Reference-Cited by-同舟云学术

Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma

Published:1999-10 Issue:10 Volume:5 Page:1171-1177
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Bendandi Maurizio,Gocke Christopher D.,Kobrin Carol B.,Benko Floyd A.,Sternas Lars A.,Pennington Robin,Watson Thelma M.,Reynolds Craig W.,Gause Barry L.,Duffey Patricia L.,Jaffe Elaine S.,Creekmore Stephen P.,Longo Dan L.,Kwak Larry W.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm1099_1171.pdf

Reference31 articles.

1. Stevenson, G.T. & Stevenson, F.K. Antibody to molecularly-defined antigen confined to a tumor cell surface. Nature 254, 714–716 ( 1975).

2. Lynch, R.G. et al. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA 69, 1540– 1544 (1972).

3. Kwak, L.W. et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209–1215 (1992).

4. Hsu, F.J. et al. Tumor-specific idiotype vaccines in the treatment of patients with B-Cell lymphoma–Long term results of a clinical trial. Blood 89, 3129–3135 ( 1997).

5. Greenberg, P.D. Adoptive T-cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281–355 (1991).

Cited by 528 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial;Nature Communications;2024-08-11

2. Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review;Pharmaceuticals;2024-02-21

3. Lymphoma Vaccines: Background and Perspectives;Cancer Immunotherapy;2024

4. Personalized Medicine's Coming of Age: One Drug, One Patient;Clinical Cancer Research;2023-09-21

5. First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma;2023-09-21